Artificial Intelligence: Industry Wants FDA To Boost Access To Databases, Clarify Use In Assessing Drug Efficacy
Executive Summary
BIO, PhRMA, Genentech, Regeneron, AAM discuss transparency in use of AI, intellectual property protection, what constitutes AI, and its application in postmarketing safety surveillance.
You may also be interested in...
AI In Drug Development: FDA Wants To Know How To Assure Data Integrity, Transparency, Reliability
US FDA asks stakeholders how they are addressing bias, reproducibility and data privacy in application of AI/ML. Discussion paper describes current and potential uses of artificial intelligence and machine learning in drug development.
FDA’s CDER Is Fostering Use Of Artificial Intelligence In Drug Development
Center for Drug Evaluation and Research plans to issue a request for information this year to engage stakeholders on issues related to AI and machine learning. It received 175 AI/ML submissions in 2022, up from 14 in 2020.
FTC Commissioner Recusal Decisions Should Be Public, US Chamber Of Commerce Says
Chamber files petition to have FTC amend its disqualification rules to have commissioners explain their rejection of recusal requests. FTC is seeking public comments on the petition.